Full text is available at the source.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects nearly one-third of adults worldwide.
- The disease ranges from simple fat accumulation to severe liver conditions, including cirrhosis and cancer.
- Fibrosis stage is the primary factor influencing liver health outcomes and cardiovascular mortality risk.
- Lifestyle changes resulting in at least 10% weight loss can lead to fibrosis regression in some patients, but sustained success is achieved in fewer than 15%.
- Resmetirom and semaglutide have been approved for treating MASH, showing significant improvements in liver histology in phase 3 trials.
- The development of other potential treatments, such as tirzepatide and efruxifermin, is underway, with several advancing to phase 3 trials.
- Future strategies include long-term outcome trials and the integration of precision medicine and comprehensive care models to improve patient outcomes.
Simplified